SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
Public ClinicalTrials.gov record NCT02013375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Related donor stem cell transplantation using the alemtuzumab/ TBI platform has been shown to be a safe strategy to cure severe sickle cell disease. However, due to a lack of suitable donors, many patients cannot benefit from this strategy. Alternative donor sources are desperately needed to fill this gap. Nearly all patients will have a haploidentical family member who would be able to donate. The use of post transplantation cyclophosphamide has greatly improved the outcome of haploidentical stem cell transplantation. The investigators propose to combine this with alemtuzumab/TBI conditioning.
Study identification
- NCT ID
- NCT02013375
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Interventions
- Haploidentical Transplant Procedure
- Alemtuzumab Drug
- Total Body Irradiation Radiation
- Cyclophosphamide Drug
- Sirolimus Drug
Procedure · Drug · Radiation
Eligibility (public fields only)
- Age range
- 16 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 9, 2014
- Primary completion
- May 30, 2014
- Completion
- Sep 6, 2018
- Last update posted
- Aug 27, 2019
2014 – 2018
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Illinois Cancer Center | Chicago | Illinois | 60612 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Sickle Cell Disease trials
Other public records listing Sickle Cell Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07776444: Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography Recruiting
- NCT07656415: A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) Recruiting
- NCT02447874: Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease Recruiting
- NCT07616154: Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Recruiting
- NCT07708350: Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease Not yet recruiting
- NCT01499888: Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02013375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2019 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02013375 live on ClinicalTrials.gov.